Stroke:取栓成功后血管再闭塞的危险因素

2018-12-26 杨中华 脑血管病及重症文献导读

随机对照试验发现血管内血栓切除术是大动脉闭塞性急性缺血性卒中最有效的治疗方法。然而,目标血管再通后的再闭塞率为3-9%。快速、持续和完全再灌注是良好临床预后的最重要的可修改预测因素,2018年11月来自瑞士的Pascal J. Mosimann等在 Stroke 上公布了他们的研究结果,他们利用一项来自于单中心的连续急性缺血性卒中前瞻性队列的数据,探讨了成功血管内血栓切除术后48h 内再闭塞的流行


随机对照试验发现血管血栓切除术是大动脉闭塞性急性缺血性卒中最有效的治疗方法。然而,目标血管再通后的再闭塞率为3-9%。快速、持续和完全再灌注是良好临床预后的最重要的可修改预测因素,2018年11月来自瑞士的Pascal J. Mosimann等在 Stroke 上公布了他们的研究结果,他们利用一项来自于单中心的连续急性缺血性卒中前瞻性队列的数据,探讨了成功血管内血栓切除术后48h 内再闭塞的流行病学和预测因素。

共纳入了711例成功再灌注(mTICI 2b/3)的卒中患者,并且24-48h 时进行了 MRA 或CTA 检测。其中16例发生了早期再闭塞(2.3%;95% CI 1.1 - 3.3;平均延后时间为20h)。提示的预测因素包括入院时血小板较高(aOR, 1.01; 95% CI: 1.01–1.02),卒中前功能残疾(aOR, 7.12; 95% CI: 1.49–34.03),以及不明原因卒中或其他特殊发病机制(TOAST 分类)卒中(分别为:aOR, 7.19; 95% CI: 1.10–47.05 和 aOR, 36.50; 95% CI: 4.47–298.11)。当把残留栓子碎片或血栓切除部位狭窄引入到logistic回归模型后,能够显著改善识别再闭塞和无再闭塞的精确性。早期再闭塞是90天不良预后的独立预测因素(aOR for mRS ≤2, 0.13; 95% CI: 0.03–0.57)。

最终作者认为成功机械性血栓切除术后48h 内早期再闭塞是非常罕见的,但是与不良预后有关。入院时较高的血小板和残留栓子碎片或血栓切除部位狭窄的患者处于再闭塞的高风险之中。作者认为对术中造影仔细再评价能够预防或纠正再闭塞。

原始出处:

Pascal J. Mosimann, et al. Predictors of Unexpected Early Reocclusion After Successful Mechanical Thrombectomy in Acute Ischemic Stroke Patients.Stroke. 2018 Nov;49(11):2643-2651. doi: 10.1161/STROKEAHA.118.021685.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2018069, encodeId=84252018069a1, content=<a href='/topic/show?id=790c8956844' target=_blank style='color:#2F92EE;'>#血管再闭塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89568, encryptionId=790c8956844, topicName=血管再闭塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21e5394, createdName=yeaweam, createdTime=Tue Nov 12 16:21:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479064, encodeId=009814e906401, content=<a href='/topic/show?id=b97f3800ee0' target=_blank style='color:#2F92EE;'>#取栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38007, encryptionId=b97f3800ee0, topicName=取栓)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99077483919, createdName=1249862am74(暂无昵称), createdTime=Fri Dec 28 08:21:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356529, encodeId=c09835652976, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Thu Dec 27 13:33:57 CST 2018, time=2018-12-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2018069, encodeId=84252018069a1, content=<a href='/topic/show?id=790c8956844' target=_blank style='color:#2F92EE;'>#血管再闭塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89568, encryptionId=790c8956844, topicName=血管再闭塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21e5394, createdName=yeaweam, createdTime=Tue Nov 12 16:21:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479064, encodeId=009814e906401, content=<a href='/topic/show?id=b97f3800ee0' target=_blank style='color:#2F92EE;'>#取栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38007, encryptionId=b97f3800ee0, topicName=取栓)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99077483919, createdName=1249862am74(暂无昵称), createdTime=Fri Dec 28 08:21:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356529, encodeId=c09835652976, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Thu Dec 27 13:33:57 CST 2018, time=2018-12-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2018069, encodeId=84252018069a1, content=<a href='/topic/show?id=790c8956844' target=_blank style='color:#2F92EE;'>#血管再闭塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89568, encryptionId=790c8956844, topicName=血管再闭塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21e5394, createdName=yeaweam, createdTime=Tue Nov 12 16:21:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479064, encodeId=009814e906401, content=<a href='/topic/show?id=b97f3800ee0' target=_blank style='color:#2F92EE;'>#取栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38007, encryptionId=b97f3800ee0, topicName=取栓)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99077483919, createdName=1249862am74(暂无昵称), createdTime=Fri Dec 28 08:21:00 CST 2018, time=2018-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356529, encodeId=c09835652976, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Thu Dec 27 13:33:57 CST 2018, time=2018-12-27, status=1, ipAttribution=)]
    2018-12-27 smartxiuxiu

    0